|
CTLA-4 can function as a negative regulator of T cell activation
|
journal
|
August 1994 |
|
Extracellular pH modulating injectable gel for enhancing immune checkpoint inhibitor therapy
|
journal
|
December 2019 |
|
A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display
|
journal
|
January 2015 |
|
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
|
journal
|
July 2021 |
|
Biased activation of human T lymphocytes due to low extracellular pH is antagonized by B7/CD28 costimulation
|
journal
|
September 2001 |
|
Features and development of Coot
|
journal
|
March 2010 |
|
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
|
journal
|
April 2013 |
|
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation
|
journal
|
August 2020 |
|
Data processing and analysis with the autoPROC toolbox
|
journal
|
March 2011 |
|
Acidification of Tumor at Stromal Boundaries Drives Transcriptome Alterations Associated with Aggressive Phenotypes
|
journal
|
February 2019 |
|
PHENIX: a comprehensive Python-based system for macromolecular structure solution
|
journal
|
January 2010 |
|
Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches
|
journal
|
February 2021 |
|
Scaling and assessment of data quality
|
journal
|
December 2005 |
|
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
|
journal
|
January 2015 |
|
Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI: acidoCEST MRI Evaluates Extracellular Tumor pH
|
journal
|
November 2013 |
|
Applications of pHLIP Technology for Cancer Imaging and Therapy
|
journal
|
July 2017 |
|
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
|
journal
|
March 2012 |
|
Variability in the pKa of histidine side-chains correlates with burial within proteins
|
journal
|
August 2002 |
|
Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment
|
journal
|
December 2020 |
|
MolProbity : all-atom structure validation for macromolecular crystallography
|
journal
|
December 2009 |
|
Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors
|
journal
|
March 2018 |
|
Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo
|
journal
|
January 1996 |
|
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
|
journal
|
April 2017 |
|
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
|
journal
|
August 2008 |
|
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
|
journal
|
October 2010 |
|
T-cells produce acidic niches in lymph nodes to suppress their own effector functions
|
journal
|
August 2020 |
|
Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody
|
journal
|
November 2020 |
|
The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics
|
journal
|
November 2013 |
|
Overview of the CCP 4 suite and current developments
|
journal
|
March 2011 |
|
Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer
|
journal
|
August 2019 |
|
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
|
journal
|
August 1995 |
|
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
|
journal
|
July 2019 |
|
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
|
journal
|
April 2017 |
|
Lack of Fucose on Human IgG1 N -Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity
|
journal
|
May 2002 |
|
XDS
|
journal
|
January 2010 |
|
T-cell regulation by CD28 and CTLA-4
|
journal
|
December 2001 |
|
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity
|
journal
|
April 2021 |
|
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
|
journal
|
April 2018 |
|
VISTA is an acidic pH-selective ligand for PSGL-1
|
journal
|
October 2019 |
|
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
|
journal
|
October 2013 |
|
A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
|
journal
|
June 2015 |
|
Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment
|
journal
|
November 2019 |
|
Targeting T Cell Co-receptors for Cancer Therapy
|
journal
|
May 2016 |
|
Non-invasive Investigation of Tumor Metabolism and Acidosis by MRI-CEST Imaging
|
journal
|
February 2020 |
|
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
|
journal
|
May 2017 |
|
Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcγRIIIa
|
journal
|
March 2004 |
|
In vivo quantitative imaging of tumor pH by nanosonophore assisted multispectral photoacoustic imaging
|
journal
|
September 2017 |
|
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
|
journal
|
January 2021 |